Juliana De Oliveira Costa

High Street
Kensington, NSW 2052, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 32 publications

Hospitalisation Is a Strong Risk Factor for Discontinuation of Sodium-Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes.

Hospitalisation Is a Strong Risk Factor for Discontinuation of Sodium-Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes.

Journal: Diabetes, obesity & metabolism

Published: May 19, 2026

Trends in publicly subsidized and private access to GLP-1 medicines indicated for type 2 diabetes in Australia, 2020-2025.

Trends in publicly subsidized and private access to GLP-1 medicines indicated for type 2 diabetes in Australia, 2020-2025.

Journal: British journal of clinical pharmacology

Published: April 17, 2026

New use of antidepressants among Australians up to 24 years of age remains high after the COVID-19 pandemic emergency era.

New use of antidepressants among Australians up to 24 years of age remains high after the COVID-19 pandemic emergency era.

Journal: The Australian and New Zealand journal of psychiatry

Published: August 16, 2025

Prevalence of SGLT2 inhibitor and GLP1 receptor agonist prescriptions in type 2 diabetes patients with and without chronic kidney disease: Analysis of an Australian primary care dataset.

Prevalence of SGLT2 inhibitor and GLP1 receptor agonist prescriptions in type 2 diabetes patients with and without chronic kidney disease: Analysis of an Australian primary care dataset.

Journal: Diabetes, obesity & metabolism

Published: April 29, 2025

Trends in use of sodium-glucose cotransporter 2 inhibitors among people with type 2 diabetes following hospitalisation with heart failure: A population-based study.

Trends in use of sodium-glucose cotransporter 2 inhibitors among people with type 2 diabetes following hospitalisation with heart failure: A population-based study.

Journal: Diabetes research and clinical practice

Published: March 24, 2025

Variation in uptake of sodium glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor analogues in adults with type 2 diabetes at high cardiovascular risk.

Variation in uptake of sodium glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor analogues in adults with type 2 diabetes at high cardiovascular risk.

Journal: European journal of clinical pharmacology

Published: March 20, 2025

Is the burden of diabetes in Australia underestimated? Comparison of diabetes ascertainment using linked administrative health data and an Australian diabetes registry.

Is the burden of diabetes in Australia underestimated? Comparison of diabetes ascertainment using linked administrative health data and an Australian diabetes registry.

Journal: Diabetes research and clinical practice

Published: December 17, 2024

Discontinuation of SGLT2i in people with type 2 diabetes following hospitalisation for heart failure: A cause for concern?

Discontinuation of SGLT2i in people with type 2 diabetes following hospitalisation for heart failure: A cause for concern?

Journal: Diabetes, obesity & metabolism

Published: October 02, 2024

Bidirectional Relationship Between Kidney Disease Progression and Cardiovascular Events in Type 2 Diabetes.

Bidirectional Relationship Between Kidney Disease Progression and Cardiovascular Events in Type 2 Diabetes.

Journal: Journal of the American College of Cardiology

Published: July 22, 2024

Use of, time to, and type of first add-on anti-hyperglycaemic therapy to metformin in Australia, 2018-2022.

Use of, time to, and type of first add-on anti-hyperglycaemic therapy to metformin in Australia, 2018-2022.

Journal: British journal of clinical pharmacology

Published: May 29, 2024

Impact of coordinated care on adherence to antihypertensive medicines among adults experiencing polypharmacy in Australia.

Impact of coordinated care on adherence to antihypertensive medicines among adults experiencing polypharmacy in Australia.

Journal: Journal of hypertension

Published: May 04, 2024

Geographic variation in sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist use in people with type 2 diabetes in New South Wales, Australia.

Geographic variation in sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist use in people with type 2 diabetes in New South Wales, Australia.

Journal: Diabetes, obesity & metabolism

Published: January 21, 2024

Showing 1-12 of 32

Last Updated: 09/26/2026